
## Dirk P Dittmer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9559882/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gain of function mutations in p53. Nature Genetics, 1993, 4, 42-46.	9.4	837
2	The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. British Journal of Cancer, 1994, 69, 409-416.	2.9	403
3	A Cluster of Latently Expressed Genes in Kaposi's Sarcoma-Associated Herpesvirus. Journal of Virology, 1998, 72, 8309-8315.	1.5	375
4	EBV MicroRNAs in Primary Lymphomas and Targeting of <i>CXCL-11</i> by ebv-mir-BHRF1-3. Cancer Research, 2008, 68, 1436-1442.	0.4	291
5	Targeting p53 as a general tumor antigen Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 11993-11997.	3.3	271
6	Modulation of the cGAS-STING DNA sensing pathway by gammaherpesviruses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4306-15.	3.3	250
7	Human cytomegalovirus infection inhibits G1/S transition. Journal of Virology, 1997, 71, 1629-1634.	1.5	212
8	Viral effects on the content and function of extracellular vesicles. Nature Reviews Microbiology, 2017, 15, 559-572.	13.6	195
9	Charting Latency Transcripts in Kaposi's Sarcoma-Associated Herpesvirus by Whole-Genome Real-Time Quantitative PCR. Journal of Virology, 2002, 76, 6213-6223.	1.5	192
10	Modulation of Cellular and Viral Gene Expression by the Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus. Journal of Virology, 2001, 75, 458-468.	1.5	189
11	Inflammatory Cytokines and the Reactivation of Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication. Virology, 2000, 266, 17-25.	1.1	178
12	Kaposi sarcoma–associated herpesvirus: immunobiology, oncogenesis, and therapy. Journal of Clinical Investigation, 2016, 126, 3165-3175.	3.9	165
13	Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood, 2007, 109, 2165-2173.	0.6	151
14	Potential pitfalls in microRNA profiling. Wiley Interdisciplinary Reviews RNA, 2012, 3, 601-616.	3.2	151
15	In Vivo-Restricted and Reversible Malignancy Induced by Human Herpesvirus-8 KSHV: A Cell and Animal Model of Virally Induced Kaposi's Sarcoma. Cancer Cell, 2007, 11, 245-258.	7.7	148
16	Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays. Cancer Research, 2003, 63, 2010-5.	0.4	145
17	Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11818-11823.	3.3	143
18	Systemically Circulating Viral and Tumor-Derived MicroRNAs in KSHV-Associated Malignancies. PLoS Pathogens, 2013, 9, e1003484.	2.1	140

#	Article	IF	CITATIONS
19	Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood, 2010, 115, 4455-4463.	0.6	139
20	Immortalization of Primary Endothelial Cells by the K1 Protein of Kaposi's Sarcoma–Associated Herpesvirus. Cancer Research, 2006, 66, 3658-3666.	0.4	132
21	Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. Nature Medicine, 2014, 20, 927-935.	15.2	130
22	Long-Term-Infected Telomerase-Immortalized Endothelial Cells: a Model for Kaposi's Sarcoma-Associated Herpesvirus Latency In Vitro and In Vivo. Journal of Virology, 2006, 80, 4833-4846.	1.5	117
23	SYBR Green-Based Real-Time Quantitative PCR Assay for Detection of West Nile Virus Circumvents False-Negative Results Due to Strain Variability. Journal of Clinical Microbiology, 2004, 42, 1511-1518.	1.8	114
24	p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 4781-4786.	3.3	113
25	Functional p53 Signaling in Kaposi's Sarcoma-Associated Herpesvirus Lymphomas: Implications for Therapy. Journal of Virology, 2007, 81, 1912-1922.	1.5	107
26	Incidence and Timing of Cancer in HIV-Infected Individuals Following Initiation of Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2013, 57, 756-764.	2.9	107
27	Differential Regulation of the Overlapping Kaposi's Sarcoma-Associated Herpesvirus vGCR (orf74) and LANA (orf73) Promoters. Journal of Virology, 2001, 75, 1798-1807.	1.5	106
28	Toll-like receptor signaling controls reactivation of KSHV from latency. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11725-11730.	3.3	105
29	Methylene blue photoinactivation of RNA viruses. Antiviral Research, 2004, 61, 141-151.	1.9	104
30	More on HIV-Associated Kaposi's Sarcoma. New England Journal of Medicine, 2008, 358, 535-536.	13.9	102
31	Experimental Transmission of Kaposi's Sarcoma–Associated Herpesvirus (Kshv/Hhv-8) to Scid-Hu Thy/Liv Mice. Journal of Experimental Medicine, 1999, 190, 1857-1868.	4.2	100
32	Interferon-Î <sup>3</sup> Production by Neutrophils during Bacterial Pneumonia in Mice. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1391-1401.	2.5	98
33	Diagnosis and Treatment of Kaposi Sarcoma. American Journal of Clinical Dermatology, 2017, 18, 529-539.	3.3	98
34	The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. Journal of Clinical Investigation, 2006, 116, 735-742.	3.9	93
35	Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)—an update. Current Opinion in Virology, 2013, 3, 238-244.	2.6	92
36	Expression Profile of MicroRNAs in Epstein-Barr Virus-Infected AGS Gastric Carcinoma Cells. Journal of Virology, 2014, 88, 1389-1393.	1.5	84

#	Article	IF	CITATIONS
37	Nef Secretion into Extracellular Vesicles or Exosomes Is Conserved across Human and Simian Immunodeficiency Viruses. MBio, 2018, 9, .	1.8	84
38	Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood, 2009, 113, 5938-5941.	0.6	82
39	Prognostic value of B cells in cutaneous melanoma. Genome Medicine, 2019, 11, 36.	3.6	81
40	Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood, 2011, 118, e32-e39.	0.6	77
41	Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood, 2008, 111, 2347-2353.	0.6	71
42	The Rta/Orf50 Transactivator Proteins of the Gamma-Herpesviridae. , 2007, 312, 71-100.		71
43	Role of Notch Signal Transduction in Kaposi's Sarcoma-Associated Herpesvirus Gene Expression. Journal of Virology, 2005, 79, 14371-14382.	1.5	70
44	Reactivation of Kaposi's sarcoma-associated herpesvirus by natural products from Kaposi's sarcoma endemic regions. International Journal of Cancer, 2007, 120, 321-328.	2.3	70
45	The Tumor Microenvironment Controls Primary Effusion Lymphoma Growth in Vivo. Cancer Research, 2004, 64, 4790-4799.	0.4	69
46	An Important Role for Mitochondrial Antiviral Signaling Protein in the Kaposi's Sarcoma-Associated Herpesvirus Life Cycle. Journal of Virology, 2014, 88, 5778-5787.	1.5	68
47	Largeâ€scale, crossâ€flow based isolation of highly pure and endocytosisâ€competent extracellular vesicles. Journal of Extracellular Vesicles, 2018, 7, 1541396.	5.5	68
48	Liposomal daunorubicin as treatment for Kaposi's sarcoma. International Journal of Nanomedicine, 2007, 2, 277-88.	3.3	66
49	mTOR Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis. Cancer Research, 2013, 73, 2235-2246.	0.4	65
50	Distinct p53, p53:LANA, and LANA Complexes in Kaposi's Sarcoma-Associated Herpesvirus Lymphomas. Journal of Virology, 2010, 84, 3898-3908.	1.5	62
51	Epstein–Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation. EBioMedicine, 2016, 9, 148-160.	2.7	61
52	Regulation and Autoregulation of the Promoter for the Latency-associated Nuclear Antigen of Kaposi's Sarcoma-associated Herpesvirus. Journal of Biological Chemistry, 2004, 279, 16822-16831.	1.6	60
53	Pre-Micro RNA Signatures Delineate Stages of Endothelial Cell Transformation in Kaposi Sarcoma. PLoS Pathogens, 2009, 5, e1000389.	2.1	60
54	Faster quantitative real-time PCR protocols may lose sensitivity and show increased variability. Nucleic Acids Research, 2005, 33, e182-e182.	6.5	58

#	Article	IF	CITATIONS
55	Rapamycin With Antiretroviral Therapy in AIDS-Associated Kaposi Sarcoma. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 447-454.	0.9	58
56	Viral Profiling Identifies Multiple Subtypes of Kaposi's Sarcoma. MBio, 2014, 5, e01633-14.	1.8	58
57	The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia, 2010, 24, 1781-1784.	3.3	57
58	Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes. MBio, 2017, 8, .	1.8	57
59	Comparison of the Rta/Orf50 Transactivator Proteins of Gamma-2-Herpesviruses. Journal of Virology, 2004, 78, 5491-5499.	1.5	56
60	Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet, The, 2020, 395, 1195-1207.	6.3	56
61	Azidothymidine inhibits NF-κB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood, 2005, 106, 235-240.	0.6	51
62	Burkitt Lymphoma in Brazil Is Characterized by Geographically Distinct Clinicopathologic Features. American Journal of Clinical Pathology, 2008, 130, 946-956.	0.4	51
63	Hsp90 Inhibitors Are Efficacious against Kaposi Sarcoma by Enhancing the Degradation of the Essential Viral Gene LANA, of the Viral Co-Receptor EphA2 as well as Other Client Proteins. PLoS Pathogens, 2012, 8, e1003048.	2.1	51
64	Modern Techniques for the Isolation of Extracellular Vesicles and Viruses. Journal of NeuroImmune Pharmacology, 2020, 15, 459-472.	2.1	51
65	Early Experience after Developing a Pathology Laboratory in Malawi, with Emphasis on Cancer Diagnoses. PLoS ONE, 2013, 8, e70361.	1.1	51
66	Epstein–Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11379-E11387.	3.3	48
67	Whole-Genome Transcription Profiling of Rhesus Monkey Rhadinovirus. Journal of Virology, 2005, 79, 8637-8650.	1.5	45
68	Multiple pathways for Epsteinâ€Barr virus episome loss from nasopharyngeal carcinoma. International Journal of Cancer, 2008, 123, 2105-2112.	2.3	45
69	Methylene blue photoinactivation abolishes West Nile virus infectivity in vivo. Antiviral Research, 2005, 68, 84-87.	1.9	44
70	Baboon model for West Nile Virus infection and vaccine evaluation. Virology, 2006, 355, 44-51.	1.1	43
71	Latent Kaposi's Sarcoma-Associated Herpesvirus Infection of Monocytes Downregulates Expression of Adaptive Immune Response Costimulatory Receptors and Proinflammatory Cytokines. Journal of Virology, 2012, 86, 3916-3923.	1.5	43
72	Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop. Pathogens and Immunity, 2020, 5, 143.	1.4	42

#	Article	IF	CITATIONS
73	Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SIV-positive and SIV-negative rhesus macaques. Journal of Medical Primatology, 2004, 33, 1-9.	0.3	41
74	Tousled-like Kinases Modulate Reactivation of Gammaherpesviruses from Latency. Cell Host and Microbe, 2013, 13, 204-214.	5.1	41
75	RIC-I Detects Kaposi's Sarcoma-Associated Herpesvirus Transcripts in a RNA Polymerase III-Independent Manner. MBio, 2018, 9, .	1.8	41
76	Viral latency locus augments B-cell response in vivo to induce chronic marginal zone enlargement, plasma cell hyperplasia, and lymphoma. Blood, 2013, 121, 2952-2963.	0.6	40
77	Moving Forward in HIV-Associated Cancer. Journal of Clinical Oncology, 2014, 32, 876-880.	0.8	40
78	Extracellular vesicles from Kaposi Sarcoma-associated herpesvirus lymphoma induce long-term endothelial cell reprogramming. PLoS Pathogens, 2019, 15, e1007536.	2.1	40
79	Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Current Opinion in Oncology, 2007, 19, 452-457.	1.1	38
80	The Open Chromatin Landscape of Kaposi's Sarcoma-Associated Herpesvirus. Journal of Virology, 2013, 87, 11831-11842.	1.5	38
81	High-Density Amplicon Sequencing Identifies Community Spread and Ongoing Evolution of SARS-CoV-2 in the Southern United States. Cell Reports, 2020, 33, 108352.	2.9	38
82	Pilot Study of Oral Valganciclovir Therapy in Patients With Classic Kaposi Sarcoma. Journal of Infectious Diseases, 2011, 203, 1082-1086.	1.9	37
83	Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A. Virology, 2012, 433, 220-225.	1.1	37
84	Maribavir Inhibits Epstein-Barr Virus Transcription in Addition to Viral DNA Replication. Journal of Virology, 2009, 83, 12108-12117.	1.5	36
85	Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi. International Journal of Cancer, 2017, 140, 2509-2516.	2.3	35
86	Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4762-8.	3.3	34
87	Impact of Anti–PD-1 and Anti–CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. Clinical Infectious Diseases, 2021, 73, e1973-e1981.	2.9	34
88	Hodgkin lymphoma, HIV, and Epstein–Barr virus in Malawi: Longitudinal results from the Kamuzu Central Hospital Lymphoma study. Pediatric Blood and Cancer, 2017, 64, e26302.	0.8	33
89	Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathogens, 2018, 14, e1007267.	2.1	32
90	Expression of the Antisense-to-Latency Transcript Long Noncoding RNA in Kaposi's Sarcoma-Associated Herpesvirus. Journal of Virology, 2017, 91, .	1.5	31

#	Article	IF	CITATIONS
91	Cytokine Homologs of Human Gammaherpesviruses. Journal of Interferon and Cytokine Research, 2012, 32, 53-59.	0.5	29
92	NLRX1 negatively modulates type I IFN to facilitate KSHV reactivation from latency. PLoS Pathogens, 2017, 13, e1006350.	2.1	29
93	Tissue Specificity of the Kaposi's Sarcoma-Associated Herpesvirus Latent Nuclear Antigen (LANA/orf73) Promoter in Transgenic Mice. Journal of Virology, 2002, 76, 11024-11032.	1.5	28
94	Treatment of Kaposi Sarcoma-Associated Herpesvirus-Associated Cancers. Frontiers in Microbiology, 2012, 3, 141.	1.5	28
95	Novel Kaposi's Sarcoma-Associated Herpesvirus Homolog in Baboons. Journal of Virology, 2003, 77, 8159-8165.	1.5	27
96	Clinical Factors Associated with Long-Term Complete Remission versus Poor Response to Chemotherapy in HIV-Infected Children and Adolescents with Kaposi Sarcoma Receiving Bleomycin and Vincristine: A Retrospective Observational Study. PLoS ONE, 2016, 11, e0153335.	1.1	27
97	As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clinical Infectious Diseases, 2018, 67, 251-260.	2.9	27
98	Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma. MBio, 2019, 10, .	1.8	27
99	Real-Time Quantitative PCR Analysis of Viral Transcription. , 2005, 292, 449-480.		26
100	Restricted Kaposi's Sarcoma (KS) Herpesvirus Transcription in KS Lesions from Patients on Successful Antiretroviral Therapy. MBio, 2011, 2, e00138-11.	1.8	26
101	Maribavir Inhibits Epstein-Barr Virus Transcription through the EBV Protein Kinase. Journal of Virology, 2013, 87, 5311-5315.	1.5	26
102	Latency Locus Complements MicroRNA 155 Deficiency <i>In Vivo</i> . Journal of Virology, 2013, 87, 11908-11911.	1.5	25
103	Translational Model of Zika Virus Disease in Baboons. Journal of Virology, 2018, 92, .	1.5	25
104	Extracellular vesicles in virus infection and pathogenesis. Current Opinion in Virology, 2020, 44, 129-138.	2.6	25
105	SARS-CoV-2 Seroprevalence among a Southern U.S. Population Indicates Limited Asymptomatic Spread under Physical Distancing Measures. MBio, 2020, 11, .	1.8	25
106	Molecular and Clinical Assessment in the Treatment of AIDS Kaposi Sarcoma with Valproic Acid. Clinical Infectious Diseases, 2009, 49, 1946-1949.	2.9	24
107	Phosphatase and Tensin Homolog on Chromosome 10 Is Phosphorylated in Primary Effusion Lymphoma and Kaposi's Sarcoma. American Journal of Pathology, 2011, 179, 2108-2119.	1.9	24
108	Ribosomal Protein S6 Interacts with the Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus. Journal of Virology, 2011, 85, 9495-9505.	1.5	24

#	Article	IF	CITATIONS
109	Epstein–Barr virus microRNAs and lung cancer. British Journal of Cancer, 2011, 105, 320-326.	2.9	24
110	The K1 Protein of Kaposi's Sarcoma-Associated Herpesvirus Augments Viral Lytic Replication. Journal of Virology, 2016, 90, 7657-7666.	1.5	24
111	Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011. Infectious Agents and Cancer, 2013, 8, 18.	1.2	23
112	Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation. Aids, 2017, 31, 1989-1997.	1.0	23
113	Human herpesvirus–encoded kinase induces B cell lymphomas in vivo. Journal of Clinical Investigation, 2018, 128, 2519-2534.	3.9	23
114	Promoter switching allows simultaneous transcription of LANA and K14/vGPCR of Kaposi's sarcoma-associated herpesvirus. Virology, 2006, 350, 192-205.	1.1	22
115	Poisson factor models with applications to non-normalized microRNA profiling. Bioinformatics, 2013, 29, 1105-1111.	1.8	22
116	Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids in African-American Women. Journal of Women's Health, 2015, 24, 489-495.	1.5	21
117	KSHV viral load and Interleukinâ€6 in HIVâ€associated pediatric Kaposi sarcoma—Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions. International Journal of Cancer, 2019, 144, 110-116.	2.3	21
118	Virus expression detection reveals RNA-sequencing contamination in TCGA. BMC Genomics, 2020, 21, 79.	1.2	21
119	High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group. PLoS ONE, 2015, 10, e0131001.	1.1	21
120	Viral Latent Proteins as Targets for Kaposis Sarcoma and Kaposis Sarcoma-associated Herpesvirus (KSHV / HHV-8) Induced Lymphoma. Current Drug Targets Infectious Disorders, 2003, 3, 129-135.	2.1	20
121	Disruption of LANA in Rhesus Rhadinovirus Generates a Highly Lytic Recombinant Virus. Journal of Virology, 2009, 83, 9786-9802.	1.5	19
122	Characteristics and survival for HIVâ€essociated multicentric Castleman disease in Malawi. Journal of the International AIDS Society, 2015, 18, 20122.	1.2	19
123	Runaway Kaposi Sarcoma-associated herpesvirus replication correlates with systemic IL-10 levels. Virology, 2020, 539, 18-25.	1.1	19
124	Human Cytomegalovirus Gene Expression in Long-Term Infected Glioma Stem Cells. PLoS ONE, 2014, 9, e116178.	1.1	19
125	Complete Genome Sequence of Pathogenic Guinea Pig Cytomegalovirus from Salivary Gland Homogenates of Infected Animals. Genome Announcements, 2013, 1, e0005413.	0.8	17
126	Repair of a Mutation Disrupting the Guinea Pig Cytomegalovirus Pentameric Complex Acquired during Fibroblast Passage Restores Pathogenesis in Immune-Suppressed Guinea Pigs and in the Context of Congenital Infection. Journal of Virology, 2016, 90, 7715-7727.	1.5	17

#	Article	IF	CITATIONS
127	Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune status. Aids, 2017, 31, 2077-2084.	1.0	17
128	KSHV Latency Locus Cooperates with Myc to Drive Lymphoma in Mice. PLoS Pathogens, 2015, 11, e1005135.	2.1	17
129	The Viral Latency-Associated Nuclear Antigen Augments the B-Cell Response to Antigen <i>In Vivo</i> . Journal of Virology, 2010, 84, 10653-10660.	1.5	16
130	Overview of the Oral HIV/AIDS Research Alliance Program. Advances in Dental Research, 2011, 23, 28-33.	3.6	16
131	Zidovudine-based lytic-inducing chemotherapy for Epstein–Barr virus-related lymphomas. Leukemia and Lymphoma, 2014, 55, 786-794.	0.6	16
132	Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence. Aids, 2014, 28, 979-987.	1.0	16
133	Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16541-16550.	3.3	16
134	Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Associated Disease in the AIDS Patient: An Update. Cancer Treatment and Research, 2019, 177, 63-80.	0.2	16
135	What Lies Within: Coinfections and Immunity. Cell Host and Microbe, 2014, 16, 145-147.	5.1	15
136	Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. Journal of Global Oncology, 2018, 4, 1-7.	0.5	15
137	Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality. MSystems, 2018, 3, .	1.7	15
138	De novo generation of CD4 T cells against viruses present in the host during immune reconstitution. Blood, 2005, 105, 2410-2414.	0.6	14
139	Development of a fluorescence-based assay to screen antiviral drugs against Kaposi's sarcoma–associated herpesvirus. Molecular Cancer Therapeutics, 2007, 6, 2360-2370.	1.9	14
140	General and Target-Specific RNA Binding Properties of Epstein-Barr Virus SM Posttranscriptional Regulatory Protein. Journal of Virology, 2009, 83, 11635-11644.	1.5	14
141	Profiling of Pre-micro RNAs and microRNAs using Quantitative Real-time PCR (qPCR) Arrays. Journal of Visualized Experiments, 2010, , .	0.2	14
142	Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease. Infectious Agents and Cancer, 2018, 13, 33.	1.2	14
143	Inclusion of Antibodies to Cell Culture Media Preserves the Integrity of Genes Encoding RL13 and the Pentameric Complex Components During Fibroblast Passage of Human Cytomegalovirus. Viruses, 2019, 11, 221.	1.5	14
144	Nuclear factor kappa B pathway associated biomarkers in AIDS defining malignancies. International Journal of Cancer, 2012, 130, 2728-2733.	2.3	13

#	Article	IF	CITATIONS
145	Toll-Like Receptor-3 Is Dispensable for the Innate MicroRNA Response to West Nile Virus (WNV). PLoS ONE, 2014, 9, e104770.	1.1	13
146	Multicentric Castleman's disease in Malawi. Lancet, The, 2014, 384, 1158.	6.3	13
147	Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma. Clinical Cancer Research, 2020, 26, 558-565.	3.2	13
148	Prevalence, incidence, and distribution of human papillomavirus types in female sex workers in Kenya. International Journal of STD and AIDS, 2020, 31, 109-118.	0.5	13
149	Do viral chemokines modulate Kaposi's sarcoma?. BioEssays, 1998, 20, 367-370.	1.2	12
150	Genome-wide real-time PCR for West Nile virus reduces the false-negative rate and facilitates new strain discovery. Journal of Virological Methods, 2010, 169, 103-111.	1.0	12
151	Animal models of tumorigenic herpesviruses — an update. Current Opinion in Virology, 2015, 14, 145-150.	2.6	12
152	Kaposi's sarcoma in Malawi. Aids, 2017, 31, 318-319.	1.0	12
153	Chlamydia trachomatis Seroprevalence and Ultrasound-Diagnosed Uterine Fibroids in a Large Population of Young African-American Women. American Journal of Epidemiology, 2018, 187, 278-286.	1.6	12
154	Novel modulators of p53-signaling encoded by unknown genes of emerging viruses. PLoS Pathogens, 2021, 17, e1009033.	2.1	12
155	Evidence for Multiple Subpopulations of Herpesvirus-Latently Infected Cells. MBio, 2022, 13, e0347321.	1.8	12
156	Enhanced Cytotoxicity without Internuclear Spread of Adenovirus upon Cell Fusion by Measles Virus Glycoproteins. Journal of Virology, 2005, 79, 1911-1917.	1.5	11
157	Identification of human papillomaviruses from formalin-fixed, paraffin-embedded pre-cancer and invasive cervical cancer specimens in Zambia: a cross-sectional study. Virology Journal, 2015, 12, 2.	1.4	11
158	Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma. Targeted Oncology, 2019, 14, 563-575.	1.7	11
159	High pretreatment plasma Epsteinâ€Barr virus (EBV) DNA level is a poor prognostic marker in HIVâ€associated, EBVâ€negative diffuse large Bâ€cell lymphoma in Malawi. Cancer Medicine, 2020, 9, 552-561.	1.3	11
160	Kaposi Sarcoma-Associated Herpesvirus Infection and Endemic Burkitt Lymphoma. Journal of Infectious Diseases, 2020, 222, 111-120.	1.9	11
161	Stage-Stratified Approach to AIDS-Related Kaposi's Sarcoma: Implications for Resource-Limited Environments. Journal of Clinical Oncology, 2014, 32, 2512-2513.	0.8	10
162	Mutant Cellular AP-1 Proteins Promote Expression of a Subset of Epstein-Barr Virus Late Genes in the Absence of Lytic Viral DNA Replication. Journal of Virology, 2018, 92, .	1.5	10

#	Article	IF	CITATIONS
163	Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma. Journal of Virology, 2020, 94, .	1.5	10
164	Regulation of Transformation and the Cell Cycle by p53. Cold Spring Harbor Symposia on Quantitative Biology, 1991, 56, 219-225.	2.0	10
165	AIDS related malignancies in Brazil. Current Opinion in Oncology, 2007, 19, 476-478.	1.1	9
166	Quantitative Analysis of the Bidirectional Viral G-Protein-Coupled Receptor and Lytic Latency-Associated Nuclear Antigen Promoter of Kaposi's Sarcoma-Associated Herpesvirus. Journal of Virology, 2012, 86, 9683-9695.	1.5	9
167	Dual inhibition of phosphatidylinositol 3-kinase/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma. Leukemia and Lymphoma, 2015, 56, 263-266.	0.6	9
168	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 52-57.	0.9	9
169	Genome Sequences of Diverse Human Cytomegalovirus Strains with Utility in Drug Screening and Vaccine Evaluation. Genome Announcements, 2017, 5, .	0.8	9
170	Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome–like Clinical Presentation in Human Immunodeficiency Virus–infected Children in Malawi. Clinical Infectious Diseases, 2019, 69, 2022-2025.	2.9	9
171	DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma. PLoS ONE, 2020, 15, e0233116.	1.1	9
172	Burden of respiratory viral infection in persons with human immunodeficiency virus. Influenza and Other Respiratory Viruses, 2020, 14, 465-469.	1.5	9
173	Kaposi's sarcoma in the era of HAART-an update on mechanisms, diagnostics and treatment. AIDS Reviews, 2005, 7, 56-61.	0.5	9
174	Efficiency clustering for low-density microarrays and its application to QPCR. BMC Bioinformatics, 2010, 11, 386.	1.2	8
175	Not like a wrecking ball: EBV fine-tunes MYC lymphomagenesis. Blood, 2014, 123, 460-461.	0.6	8
176	Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2–p53 complex formation. Journal of Antibiotics, 2017, 70, 962-966.	1.0	8
177	Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy. PLoS ONE, 2018, 13, e0197665.	1.1	8
178	Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 422-429.	0.9	8
179	The ORF45 Protein of Kaposi Sarcoma-Associated Herpesvirus Is an Inhibitor of p53 Signaling during Viral Reactivation. Journal of Virology, 2021, 95, e0145921.	1.5	8
180	AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma. Clinical Cancer Research, 2022, 28, 2646-2656.	3.2	8

#	Article	IF	CITATIONS
181	Rapalogs in viral cancers. Expert Opinion on Investigational Drugs, 2012, 21, 135-138.	1.9	7
182	Complete Genome Sequences of <i>Mandrillus leucophaeus</i> and <i>Papio ursinus</i> Cytomegaloviruses. Genome Announcements, 2015, 3, .	0.8	7
183	The Oral HIV/AIDS Research Alliance Program: lessons learned and future directions. Oral Diseases, 2016, 22, 128-134.	1.5	7
184	Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections. Journal of Virology, 2018, 92, .	1.5	7
185	Purification Methods and the Presence of RNA in Virus Particles and Extracellular Vesicles. Viruses, 2020, 12, 917.	1.5	7
186	Alisertib, an Aurora a Kinase Inhibitor, Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma Cells. Blood, 2015, 126, 1551-1551.	0.6	7
187	Complete Genome Sequence of Cell Culture-Attenuated Guinea Pig Cytomegalovirus Cloned as an Infectious Bacterial Artificial Chromosome. Genome Announcements, 2014, 2, .	0.8	6
188	Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-11² Secretion: A Primary Human Monocyte Model. PLoS ONE, 2015, 10, e0136708.	1.1	6
189	Whole-genome sequencing of Kaposi sarcoma-associated herpesvirus (KSHV/HHV8) reveals evidence for two African lineages. Virology, 2022, 568, 101-114.	1.1	6
190	Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Compensates for Interleukin-6 in Initial B Cell Activation. Journal of Virology, 2016, 90, 2150-2154.	1.5	5
191	KSHV-Associated Disease in the AIDS Patient. Cancer Treatment and Research, 2007, 133, 129-139.	0.2	5
192	AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL) Journal of Clinical Oncology, 2018, 36, TPS2597-TPS2597.	0.8	5
193	Differential IgM expression distinguishes two types of pediatric Burkitt lymphoma in mouse and human. Oncotarget, 2016, 7, 63504-63513.	0.8	5
194	A prospective study of asymptomatic SARS-CoV-2 infection among individuals involved in academic research under limited operations during the COVID-19 pandemic. PLoS ONE, 2022, 17, e0267353.	1.1	5
195	Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas. Frontiers in Oncology, 2021, 11, 670275.	1.3	4
196	Exosome-Encased Nucleic Acid Scaffold Chemotherapeutic Agents for Superior Anti-Tumor and Anti-Angiogenesis Activity. ACS Bio & Med Chem Au, 2022, 2, 140-149.	1.7	4
197	An Appraisal of Non–AIDS-Defining Cancers. Archives of Internal Medicine, 2010, 170, 1345.	4.3	3
198	Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden. JAMA Oncology, 2017, 3, 1429.	3.4	3

#	Article	IF	CITATIONS
199	Abstract 4781: EBV infection of mammary epithelial cells promotes malignant transformation , 2013, , .		3
200	Molecular profiling of breast and lung cancer in women with HIV reveals high tumor mutational burden. Aids, 2022, 36, 567-571.	1.0	3
201	"Virus hunting―using radial distance weighted discrimination. Annals of Applied Statistics, 2015, 9, .	0.5	2
202	Zika vaccine: Clinical trial and error?. Science, 2016, 353, 1375-1375.	6.0	2
203	Direct Stochastic Optical Reconstruction Microscopy of Extracellular Vesicles in Three Dimensions. Journal of Visualized Experiments, 2021, , .	0.2	2
204	A Pilot Trial of Valproic Acid in Patients with Kaposi's Sarcoma: A Multi-Center Trial of the AIDS Malignancy Consortium Blood, 2007, 110, 2279-2279.	0.6	2
205	AIDS malignancy consortium (AMC) 095: A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV-associated solid tumors (ST) with expansion cohorts in HIV-associated solid tumors and classical Hodgkin lymphoma (cHL) Journal of Clinical Oncology, 2018, 36, TPS44-TPS44.	0.8	2
206	Genome Sequence of Human Cytomegalovirus Ig-KG-H2, a Variant of Strain KG Propagated in the Presence of Neutralizing Antibodies. Microbiology Resource Announcements, 2020, 9, .	0.3	2
207	Kaposi-Sarcoma-Associated Herpesvirus. Translational Research in Biomedicine, 2008, , 170-185.	0.4	1
208	Reply to P. De Paoli et al. Journal of Clinical Oncology, 2014, 32, 3079-3080.	0.8	1
209	Oral Cytokine Levels Are More Linked to Levels of Plasma and Oral HIV-1 RNA Than to CD4+ T-Cell Counts in People With HIV. Open Forum Infectious Diseases, 2020, 7, ofaa047.	0.4	1
210	Intra-Host Evolution Provides for Continuous Emergence of SARS-CoV-2 Variants. SSRN Electronic Journal, 0, , .	0.4	1
211	KSHV Latent Genes and Their Regulation. , 2009, , 495-520.		1
212	Kaposi Sarcoma-Associated Herpesvirus (KSHV) or Human Herpesvirus 8 (HHV-8). , 2014, , 61-74.		1
213	Abstract 4: Antitumor activity of DLX1008, a single chain antibody fragment binding to VEGF-A, in in vivo preclinical models of Kaposi sarcoma and glioblastoma. Cancer Research, 2018, 78, 4-4.	0.4	1
214	In Vivo-Restricted and Reversible Malignancy Induced by Human Herpesvirus-8 KSHV: A Cell and Animal Model of Virally Induced Kaposi's Sarcoma. Cancer Cell, 2007, 11, 471.	7.7	0
215	Rapamycin Inhibits Autocrine Signaling (IL-6, IL-10) in Viral Lymphomas. Clinical Immunology, 2007, 123, S154-S155.	1.4	0
216	Determinants of mTOR inhibitor therapy in AIDS-associated malignancies. Infectious Agents and Cancer, 2012, 7, .	1.2	0

#	Article	IF	CITATIONS
217	The limits of multiplexing. Wiley Interdisciplinary Reviews: Computational Statistics, 2015, 7, 394-399.	2.1	0
218	VIRONOMICS: The Study of Viral Genomics in Human Cancer and Disease. , 2015, , 345-366.		0
219	2264. The Burden of Respiratory Viral Illness in HIV-Infected Patients. Open Forum Infectious Diseases, 2018, 5, S670-S670.	0.4	Ο
220	Role of NF-Î $^\circ$ B Inhibitors in HIV-Related Malignancies. , 2010, , 95-110.		0
221	Abstract 5038: Why is rapamycin effective against Kaposi sarcoma? An analysis of molecular pathways reveals posttranslational silencing of PTEN. , 2011, , .		0
222	KSHV Latency Locus Augments B Cell Response In Vivo. Blood, 2011, 118, 1115-1115.	0.6	0
223	Viral Ortholog Complements Mir-155 Deficiency-Associated Abnormalities and Together with Additional Viral Mirnas Causes B Cell Hyperplasia and B Cell Lymphoma. Blood, 2012, 120, 4866-4866.	0.6	0
224	Kaposi Sarcoma-Associated Herpesvirus (KSHV) or Human Herpesvirus 8 (HHV-8). , 2013, , 1-9.		0
225	Abstract B39: Multitarget approach against PI3K, Aurora kinase, and BRD4 leads to improved antitumor activity in Myc-overexpressing lymphoma cells. , 2015, , .		0
226	A prospective study to evaluate outcomes of AIDS-related lymphomas at a tertiary referral cancer centre Journal of Clinical Oncology, 2017, 35, e19012-e19012.	0.8	0
227	Kaposi Sarcoma-Associated Herpesvirus (KSHV) or Human Herpesvirus 8 (HHV-8). , 2018, , 1179-1186.		0
228	Editorial overview: Viral immunology. Current Opinion in Virology, 2020, 44, v-vi.	2.6	0
229	The flu vaccine in cancer patients: insights from other immune-suppressed populations. Oncology, 2010, 24, 1171.	0.4	0
230	ANALYSIS AND QC FOR REAL-TIME QPCR ARRAYS OF HUMAN MICRORNAS. , 0, , 47-69.		0